“The African Development Bank has finalized a $15 million loan to Biovac to build a multi-vaccine manufacturing facility in Cape Town, aiming to produce 500 million doses annually by 2028. This facility will make Biovac Africa’s first end-to-end producer of oral cholera and inactivated polio vaccines, reducing reliance on imports and boosting health sovereignty.”
South Africa’s biotechnology industry has taken a significant leap forward with the announcement that the African Development Bank (AfDB) will provide $15 million in financing to Biovac, the country’s leading biopharmaceutical company. This funding will support the construction of a new multi-vaccine manufacturing facility in Cape Town, a project that promises to transform Africa’s vaccine landscape by expanding local production capacity and reducing dependence on imports.
Africa’s Vaccine Dependency
Currently, Africa imports more than 99% of the vaccines it uses, despite carrying a disproportionate share of the global burden of vaccine-preventable diseases. This dependency became starkly visible during the COVID-19 pandemic, when African nations struggled to secure timely access to vaccines. The Biovac expansion project directly addresses this vulnerability by building local capacity to produce critical vaccines.
Scope of the Biovac Facility
The new facility is expected to be completed by 2028 and will initially focus on producing oral cholera vaccines. Later, production will expand to include inactivated polio vaccines (IPV), pneumococcal conjugate vaccines (PCV), and meningitis vaccines (MenX). Once operational, Biovac’s facility will have the capacity to manufacture 500 million doses annually, positioning South Africa as a continental leader in vaccine production.
Strategic Partnerships
Biovac’s expansion is supported by technology-transfer partnerships with global pharmaceutical leaders including Sanofi, the International Vaccine Institute, Biological E Limited, EuBiologics, and Bharat Biotech. These collaborations will ensure that Biovac can produce vaccines that meet international standards, while also fostering knowledge transfer and capacity building within Africa.
Health Sovereignty and Regional Value Chains
AfDB Vice President Solomon Quaynor emphasized that this investment is about “building Africa’s health sovereignty.” By enabling Africa to produce its own vaccines, the project strengthens regional value chains and industrial capabilities, ensuring that the continent can respond more effectively to future health emergencies.
Integration with Global Health Initiatives
The Biovac project is designed to integrate with the World Health Organization’s Gavi African Vaccine Manufacturing Accelerator, a $1.2 billion mechanism that rewards African manufacturers with milestone payments once they achieve WHO prequalification. This ensures that Biovac’s vaccines will not only serve local populations but also be eligible for procurement through global health initiatives.
Economic and Social Impact
Beyond public health, the facility will generate significant economic benefits. It will create jobs in biotechnology, manufacturing, and logistics, while also stimulating South Africa’s broader pharmaceutical industry. The project aligns with South Africa’s industrial policy goals of fostering innovation, building local capacity, and reducing reliance on imports.
Challenges and Considerations
While the project is ambitious, challenges remain. Vaccine production requires stringent quality control, regulatory compliance, and sustained investment in research and development. Ensuring affordability and equitable distribution across Africa will also be critical to the project’s success.
Conclusion
The AfDB’s investment in Biovac represents a turning point for Africa’s biotechnology sector. By building Africa’s first end-to-end oral cholera vaccine manufacturing facility and the continent’s first local production of inactivated polio vaccine, Biovac is helping to transform Africa from a consumer of imported vaccines into a producer of critical health solutions. This project not only strengthens Africa’s health sovereignty but also lays the foundation for a more resilient and self-sufficient future.
